Toulouse Oncopole Campus’ new research team to advance immuno-oncology research

The ‘Toulouse Cancer Santé’ Foundation and the Pierre Fabre Research Institute have launched a new research team within the Cancer Research Centre of Toulouse (CRCT).

This team, which will receive 5 years of funding in equal parts from the ‘Toulouse Cancer Santé’ Foundation and the Pierre Fabre Research Institute, will be dedicated to research in immuno-oncology.

The team will be led by a world-class physician-scientist, specialised in translational medicine, with a proven expertise in immuno-oncology. The aim of translational medicine is to expedite therapeutic innovations by strengthening the connections between basic and clinical research.

To recruit this lead physician-scientist, a call for applications was launched on June 2nd, through advertisements in various scientific journals. The final decision on who will head the team will be made by the International Scientific Council of the Toulouse Cancer Santé Foundation and the Cancer University Institute of Toulouse (IUCT).

Philippe Douste-Blazy, President of the ‘Toulouse Cancer Santé’ Foundation, commented: “The recruitment of a prominent oncologist, with a combined expertise in translational medicine and immuno-oncology, is a testament to the Foundation’s ambition for the Oncopole: attract and finance, here in Toulouse, the doctors and scientists who will make tomorrow’s discoveries, and elevate the Toulouse campus to a level of international excellence.” 

Supporting research on the Toulouse Oncopole site

Through this initiative, the ‘Toulouse Cancer Santé’ Foundation and the Pierre Fabre Research Institute aim at strengthening their collaboration to support research on the Toulouse Oncopole site, therefore contributing to the advance of knowledge in oncology and the discovery of new treatments for patients.

Commenting on the announcement, Bertrand Parmentier, CEO of Pierre Fabre Laboratories, said: “Focusing on translational medicine and immuno-oncology, this team will work closely with our own research teams in both of these promising areas, as a way to boost the clinical evaluation of, and access to, new treatments for the benefit of patients. This investment also confirms our commitment to the development of the Oncopole and of Toulouse as an internationally recognised site for research in oncology.”